What is Oculogica?
Oculogica operates at the intersection of ophthalmology and neurology, specializing in the development of advanced eye-tracking solutions that provide objective insights into brain function. By prioritizing rigorous regulatory compliance and technical precision, the firm addresses critical unmet needs within the healthcare sector. Its product suite is engineered to assist clinicians in evaluating neurological health through non-invasive, data-driven methodologies, positioning the company as a pivotal player in the diagnostic technology market. The organization maintains a robust quality management system, ensuring that every iteration of its diagnostic tools meets the stringent requirements of both healthcare professionals and patient safety standards.
How much funding has Oculogica raised?
Oculogica has raised a total of $2.4M across 3 funding rounds:
Private Equity
$599K
Private Equity
$1.7M
Debt
$104K
Private Equity (2014): $599K, investors not publicly disclosed
Private Equity (2016): $1.7M, investors not publicly disclosed
Debt (2021): $104K supported by PPP
Key Investors in Oculogica
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Oculogica?
With the recent influx of capital, Oculogica is well-positioned to accelerate its research and development initiatives, focusing on the scalability of its diagnostic platforms. The strategic roadmap likely involves expanding clinical utility and deepening market penetration within neurology departments globally. As the company transitions into its next phase of growth, the focus will remain on optimizing technical support infrastructure and enhancing the diagnostic accuracy of its eye-tracking systems. By leveraging this financial backing, Oculogica aims to solidify its competitive advantage in the medical technology space, potentially exploring new therapeutic applications for its core diagnostic engine while maintaining its commitment to high-standard regulatory excellence.
See full Oculogica company page
